title: Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.
abstract: OBJECTIVE
  In patients with chronic hepatitis C treated with interferon alfa, sustained normalization of alanine aminotransferase was observed in about 20%, and no predictive factor of response could be clearly identified. The aims of this study were to assess the efficacy of an escalating dose of interferon and to determine the predictive factors of response.
  
  
  METHODS
  Seventy-five patients were randomly assigned to two groups. Twenty-five patients received a dosage of 3 million units of recombinant interferon alfa-2b three times weekly for 24 weeks, and 50 patients received a dose that was increased to 5 million units at 8 weeks in nonresponders and to 10 million units 8 weeks later in persistent nonresponders. Multivariate analysis was performed to determine the features associated with response.
  
  
  RESULTS
  A sustained response was observed in 17% of the patients with constant dosage and in 19% of patients with an escalating dosage. Low pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype were found to be independent predictive factors of sustained response.
  
  
  CONCLUSIONS
  In patients with chronic hepatitis C, an escalating dosage of interferon did not improve the overall rate of response. Low pretreatment serum hepatitis C virus RNA levels and genotype other than 1b were the only predictive factors of sustained response.
authors.affiliation: Service d'Hépatologie, INSERM Unité 24, Clichy, France.
authors.forename: P
authors.initials: P
authors.lastname: Marcellin
authors.forename: M
authors.initials: M
authors.lastname: Pouteau
authors.forename: M
authors.initials: M
authors.lastname: Martinot-Peignoux
authors.forename: F
authors.initials: F
authors.lastname: Degos
authors.forename: V
authors.initials: V
authors.lastname: Duchatelle
authors.forename: N
authors.initials: N
authors.lastname: Boyer
authors.forename: C
authors.initials: C
authors.lastname: Lemonnier
authors.forename: C
authors.initials: C
authors.lastname: Degott
authors.forename: S
authors.initials: S
authors.lastname: Erlinger
authors.forename: J P
authors.initials: JP
authors.lastname: Benhamou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D006508:Hepatitis Antibodies / Q000097:blood; D006526:Hepatitis C / Q000276:immunology / Q000628:therapy* / Q000821:virology; D018937:Hepatitis C Antibodies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins
chemical_list: D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins